Registry study of fluzoparib for ovarian, tube, or peritoneal cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This is an observational (non-interventional) study that tracks how fluzoparib is used to treat ovarian, fallopian tube, or primary peritoneal cancer in real-world care. It may help doctors better understand how well the treatment works and what side effects patients experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign an informed consent form to join the study
- You are 18 years or older
- You have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer confirmed by lab testing
- Your treating doctor believes you can receive fluzoparib by itself or with other treatments
- If you could become pregnant, you will use reliable birth control during the study and for 90 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests two oral medications given after your first round of chemotherapy. The goal is to see if taking these drugs regularly can keep the cancer from coming back.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
This trial tests two oral drugs, fluzoparib and dalpiciclib, given together, for ovarian cancer that has returned or progressed shortly after platinum chemotherapy. The goal is to see if this combination can help control the cancer.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.